13-Dec-2018 | Zion Market Research
Zion Market Research has published a new report titled “Sarcopenia Market by Supplement Type (Protein Supplement, Vitamin D & Calcium Supplement, and Vitamin B12 Supplement) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Hypermarket & Supermarket): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2024”. According to the report, the global sarcopenia market was valued at approximately USD 2,203 million in 2017 and is expected to generate revenue of around USD 2,958 million by 2024, growing at a CAGR of around 4.3% between 2018 and 2024.
Sarcopenia is a condition associated with the aging that leads to the loss of muscle mass and strength over time. It mostly affects people over the age of 30. Sarcopenia affects the quality of life and reduces the level of physical activities, and causes a deficiency of vitamins and nutrition. This can lead to the withdrawal of important amino acids from the body, which can worsen the condition. The treatment options include intake of protein supplements to provide the required nutrition to the body and strength building exercises, such as weight lifting. It can be categorized into presarcopenia—loss of muscle mass, sarcopenia—loss of muscle, and severe sarcopenia involves loss of muscles that severely affects the normal functioning of the body.
Browse the full "Sarcopenia Market by Supplement Type (Protein Supplement, Vitamin D & Calcium Supplement, and Vitamin B12 Supplement) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Hypermarket & Supermarket): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2024" Report At https://www.zionmarketresearch.com/report/sarcopenia-market
The major factor likely to drive the global sarcopenia market over the forecast time period is the increasing prevalence of sarcopenia. As per the International osteoporosis foundation, the global prevalence of sarcopenia among the aging population is expected to rise from 11.1% in 2016 to 12.9% by 2045 coupled with the increasing cases of obesity and aging population. The Population Reference Bureau Report in “Aging in the United States” published the number of Americans over the age of 65 or above will be more than double by 2060, i.e., from 46 million in 2016 to over 98 million by 2060. As per the World Health Organization 2016, nearly 650 million adults globally are obese. There is no permanent cure for obesity, which has led to an increase in research and development activities for the development of better treatment options. Furthermore, change in government policies pertaining to research and development activities and disease management activities are further expected to fuel this market in the near future. However, the non-availability of new drugs is expected to limit the sarcopenia market in the upcoming years.
Sarcopenia market is segmented on the basis of supplement type and distribution channel. By supplement type, this market includes protein supplement, Vitamin D and calcium supplement, and Vitamin B12 supplement. Protein supplements are expected to dominate the market over the forecast time period. By distribution channel, the sarcopenia market includes hospital pharmacies, retail pharmacies, online pharmacies, and hypermarket and supermarket. Online pharmacies are expected to experience a rapid rate of growth over the forecast time period.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the key regions of the global sarcopenia market. North America is expected to dominate the sarcopenia market over the forecast time period, owing to the health-conscious population and well-developed healthcare infrastructure. Europe is expected to closely follow North America in terms of revenue, owing to the technological advancements for the diagnosis and treatment of sarcopenia. The Asia Pacific is expected to experience rapid growth, owing to the presence of developing economies, increased awareness among people about sarcopenia, and improvements made in healthcare facilities. Latin America and the Middle East and Africa are expected to expand considerably in the future.
Some of the major players operating in the global sarcopenia market include Abbott Laboratories, Pfizer Inc., Eli Lilly and Company, Bayer AG, Sanofi S.A., GlaxoSmithKline plc, Novartis, Cadila Healthcare, and Amway, among others.
This report segments the global sarcopenia market as follows:
Global Sarcopenia Market: Supplement Type Segment Analysis
Global Sarcopenia Market: Distribution Channel Segment Analysis
Global Sarcopenia Market: Regional Segment Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651